BioMarin Launches Firdapse In Germany And The UK
This article was originally published in The Pink Sheet Daily
Executive Summary
Biomarin's fourth orphan product, amifampridine, launched for the symptomatic treatment of Lambert Eaton myasthenic syndrome.
You may also be interested in...
Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse
FDA’s refuse-to-file letter for Firdapse in two ultra-rare neuromuscular disorders does not make judgments about the drug’s safety or efficacy, says Catalyst.
BioMarin: A Rare Disease Specialist With An Eye On The Long-Term
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.
Dispute With Departing Board Member Creates Speculation BioMarin Is For Sale
Dueling letters pose question of whether there has been a bona fide offer for the ERT-focused specialty firm.